View Older Stories
-
Cantor Fitzgerald Upgrades Replimune Group (REPL) to Overweight
-
Replimune (REPL) call put ratio 1 call to 3.7 puts as share price down 9%
-
Replimune stock tumbles 20% after FDA raises efficacy concerns
-
Replimune (REPL) Weakness Tied to FDA Briefing Documents, Shares -18%
-
Replimune (REPL) files for 25.1M share offering by selling stockholders
-
Replimune (REPL) call put ratio 1 call to 1 put amid wide price movement
-
Replimune (REPL) call put ratio 1 call to 1.3 puts with a focus on August options
-
BMO Capital Upgrades Replimune Group (REPL) to Outperform
-
Replimune (REPL) call put ratio 1.6 calls to 1 put
-
Increasing unusual put volume: AS WEN REPL BHC BTG IGV HWM CHYM BURL CIA
-
FDA accepts Replimune RP1 BLA resubmission for advanced melanoma
-
Replimune (REPL) call put ratio 1 call to 1.2 put amid sharp rally
-
Replimune presents final data for RP2 cancer treatment at oncology meeting
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
Replimune (REPL) call put ratio 1.4 calls to 1 put as share price up 83%
-
Replimune plans RP1 cancer drug resubmission after FDA talks
-
Replimune To Resubmit Melanoma Treatment For Fda Approval - WSJ
-
FDA Commissioner Marty Makary is resigning - Politico reporter on X
-
Replimune shares surge on report Trump to dismiss FDA chief Makary
-
Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX
-
Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX
-
BMO Capital Downgrades Replimune Group (REPL) to Underperform
-
Jefferies Downgrades Replimune Group (REPL) to Hold
-
JPMorgan Downgrades Replimune Group (REPL) to Underweight
-
Replimune receives FDA rejection for melanoma treatment RP1
-
Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral
-
Piper Sandler Downgrades Replimune Group (REPL) to Neutral
-
Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'
-
Replimune (REPL) gets CRL from FDA
-
Replimune (REPL) Halted on Volatility, Down 8%
-
Increasing unusual option volume: VFS CORN CODI BIZD CWAN REPL
-
Replimune Group, Inc. (REPL) Misses Q3 EPS by 1c
-
Replimune's (REPL) RP1s Likely to Get Accelerated Approval - Cantor Fitzgerald
-
Replimune presents RP1 melanoma trial data at cancer meeting
-
BMO Capital Upgrades Replimune Group (REPL) to Market Perform
-
H.C. Wainwright Upgrades Replimune Group (REPL) to Buy
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
Replimune (REPL) call put ratio 1.2 calls to 1 put as share price up 105%
-
Leerink Partners Upgrades Replimune Group (REPL) to Outperform
-
Increasing unusual put option volume: REPL LBRT ARCT CRML BYND ABAT BITF EXEL
-
Wedbush Upgrades Replimune Group (REPL) to Outperform
-
FDA accepts Replimune BLA resubmission for RP1 melanoma treatment
-
H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)
-
JPMorgan Downgrades Replimune Group (REPL) to Underweight
-
Replimune meets with FDA on melanoma treatment application
-
H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)
-
Replimune schedules FDA meeting on melanoma treatment application
-
Replimune Group (REPL) PT Lowered to $8 at Jefferies
-
Important Notice to Long-term Shareholders of Replimune Group, Inc. (REPL): Grabar Law Office Investigates Claims on Your Behalf

